Celcuity Inc represents the values of innovation, precision, and patient-centered care. As a biotechnology company, Celcuity is dedicated to developing and commercializing novel diagnostic tests to identify and treat cancer patients who can benefit from targeted therapies. Their corporate philosophy emphasizes the importance of using cutting-edge technology to improve patient outcomes and provide physicians with precise and actionable information. By harnessing the power of CELsignaling™, Celcuity strives to revolutionize therapeutic decision-making in oncology. Through their relentless pursuit of scientific advancements, Celcuity Inc aims to make a significant and positive impact in the field of precision medicine.

Celcuity Inc is primarily present in the United States.

Celcuity Inc has achieved several significant milestones in its journey. The company has made remarkable progress in the field of precision medicine and oncology diagnostics. One of the notable achievements includes its successful initial public offering (IPO), which helped to raise funds for further research and development efforts. Moreover, Celcuity has successfully established collaborations with renowned academic institutions and pharmaceutical companies, allowing for the expansion of its product pipeline and access to a broader patient population. The continued advancements in their proprietary CELsignia platform have also provided valuable insights into the molecular signatures of various cancers, enhancing physicians' ability to personalize treatment strategies.

Celcuity Inc is a biotechnology company based in Minneapolis, Minnesota. Founded in 2012, Celcuity focuses on developing innovative therapeutic solutions for the treatment of cancer. The company specializes in discovering cancer subtypes by analyzing a patient's cells to identify abnormal signaling activity. By providing this personalized information, Celcuity aims to help healthcare professionals make more informed treatment decisions. With its cutting-edge platform and collaborations with renowned institutions, Celcuity Inc is committed to advancing precision medicine and improving patient outcomes in the field of oncology.

The main competitors of Celcuity Inc in the market are large pharmaceutical companies such as Pfizer, Novartis, and Roche.

Celcuity Inc is primarily active in the biotechnology industry.

Celcuity Inc, a targeted diagnostics company, operates on a unique business model focusing on developing and commercializing novel companion diagnostic tests. By analyzing a patient's living cancer cells used in diagnostic testing, Celcuity gathers crucial data to identify abnormal signaling pathways that can guide physicians in selecting the most effective treatment. Leveraging its proprietary CELsignia platform, Celcuity aims to improve patient outcomes by enabling the identification of patients who are likely to respond favorably to specific targeted therapies. Through its innovative approach, Celcuity strives to revolutionize personalized medicine in the field of cancer diagnostics.

Celcuity의 P/E 비율은 -3.5입니다.

Celcuity의 P/S 비율은 0입니다.

Celcuity에 대한 AlleAktien 품질 점수는 2/10입니다.

Celcuity에 대한 현재 매출은 계산할 수 없습니다.

예상되는 Celcuity 이익은 -97.54 백만 USD입니다.

Celcuity Inc is a US biotechnology company specializing in the development of precision medicine solutions for the treatment of cancer. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota. Celcuity operates in two business areas: drug development and diagnostic test development. Celcuity's drug development is based on the discovery of new mechanistic target molecules that play a role in cancer formation. The company is working intensively to develop drugs that specifically target these targets to achieve better efficacy and tolerability in cancer therapy. The second business area is the development of diagnostic tests. Celcuity has developed a novel diagnostic procedure that identifies the molecular signature of cancer cells, enabling rapid and targeted diagnosis. These tests can help identify patient groups most likely to benefit from specific cancer treatments, leading to better and personalized therapies. Celcuity already offers various diagnostic tests, including the CELx HER2 Signaling Function Test, which measures the HER2 signaling pathway in tumor cells, allowing prediction of the efficacy of various HER2-targeted therapies. Celcuity's business model is based on the development of innovative solutions based on precision medicine approaches. The company collaborates with renowned research institutions and pharmaceutical companies. Celcuity is a publicly traded company financed through the sale of shares. The company has invested significantly in research and development in recent years and has acquired several patents to protect its technology. Celcuity aims to improve the lives of cancer patients through the development of better treatment options and a personalized approach. Collaboration with the medical community and the development of innovative diagnostic tests are key priorities. Overall, Celcuity is a promising biotechnology company leading in the field of precision medicine for cancer therapy. The company has made significant progress in recent years and is committed to revolutionizing cancer therapy through the provision of personalized treatments.

Celcuity은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Celcuity의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Celcuity의 ISIN은 US15102K1007입니다.

Celcuity의 WKN은 A2JAAX입니다.

Celcuity의 티커는 CELC입니다.

지난 12개월 동안 Celcuity은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Celcuity은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Celcuity의 현재 배당 수익률은 입니다.

Celcuity은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Celcuity은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Celcuity은 '건강' 섹터에 속합니다.

Celcuity의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Celcuity는 0 USD를 배당금으로 지급했습니다.

Celcuity의 배당금은 USD에 지급됩니다.